Godavari Biorefineries Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹460Cr
- +2.9% YoY
- +6.7% QoQ
- Net profit
- ₹8Cr
- +33.3% YoY
- Turned profitable QoQ
- Margin
- 9%
- +1 pp YoY
- +10.8 pp QoQ
The short version
Godavari Biorefineries expects robust growth through capacity expansions, especially in grain/maize-based ethanol distilleries. Godavari Biorefineries aims to achieve a 3x EBITDA growth by FY29, targeting INR 3000 crores topline with 10-11% EBITDA margin (Page 13).
From Godavari Bioref.'s Q3 FY26 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Godavari Biorefineries expects robust growth through capacity expansions, especially in grain/maize-based ethanol distilleries.
- The company targets a significant increase in revenue, aiming for close to INR 3,000 crores topline by 2029 with 10-11% EBITDA margin.
- Expansion of bio-based chemicals, including specialty chemicals and bio-based monomers, is a key driver for high-margin growth.
- Increasing ethanol blending mandates (E20 achieved 5 years ahead of schedule) and potential introduction of flex fuel vehicles will boost ethanol demand.
- Continuous innovation and co-creation with customers to develop green transition products underpin growth.
2 more points from Godavari Bioref.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Godavari Bioref. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Godavari Biorefineries is investing in capacity expansion, notably:
- Adding a grain-based (maize) ethanol distillery facility, with commissioning expected next quarter due to some equipment delays.
- Continuing investments in bio-based specialty chemicals capacity through debottlenecking and expansions.
- Total planned capex is estimated at INR 325 crores by FY29, with approximately 75% allocated to bio-based chemicals and 25% to ethanol.
- Strategic investments include:
- Licensing deal with Catalyxx for bio-based butanol production.
- Collaboration with Synthomer to commercialize bio-based butyl acrylate.
- Pilot plant development for dimethyl ether (DME) technology in partnership with the Institute of Chemical Technology.
2 more points from Godavari Bioref.'s call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Godavari Bioref. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has received binding supply obligations for ethanol volumes through OMC tenders for the ethanol supply year.
- Operational and financial preparations are underway to service these mandated volumes despite margin pressures from rising cane costs.
- The grain-based ethanol facility commissioning is delayed but expected by next quarter, which will support their capacity to meet orders.
2 more points from Godavari Bioref.'s call on order book
Create a free account to keep reading this call
Godavari Bioref. — Quarterly revenue & net profit
Godavari Bioref. Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 460 | 447 | +2.9% | 431 | +6.7% |
| Operating profit (EBITDA) | 43 | 36 | +19.4% | -8 | — |
| Operating margin | 9% | 8% | +1 pp | -1.8% | +10.8 pp |
| Profit before tax | 13 | 8 | +62.5% | -57 | — |
| Net profit (PAT) | 8 | 6 | +33.3% | -42 | — |
| EPS (₹) | 1.61 | 1.13 | +42.5% | -8.13 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹549 Cr, net loss ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Godavari Biorefineries's management said in earlier quarters
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Godavari Bioref. and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Godavari Bioref. Q3 FY26 results?
Godavari Biorefineries expects robust growth through capacity expansions, especially in grain/maize-based ethanol distilleries. Godavari Biorefineries aims to achieve a 3x EBITDA growth by FY29, targeting INR 3000 crores topline with 10-11% EBITDA margin (Page 13).
What is Godavari Bioref. share price analysis?
Godavari Bioref. currently shows a neutral. The stock trades at a P/E of 43.6 with a market cap of ₹1,265 Cr. Investors should review the full earnings analysis for detailed insights.
Is Godavari Bioref. planning capital expenditure?
Godavari Biorefineries is investing in capacity expansion, notably: - Adding a grain-based (maize) ethanol distillery facility, with commissioning expected next quarter due to some equipment delays.
Keep Godavari Bioref. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
